MoCRA Compliance for Korean and Japanese Cosmetic Brands

Key MoCRA Requirements for Cosmetic Brands

MoCRA赋予了FDA前所未有的化妆品监管权力。核心要求包括：

• Facility Registration — All facilities that manufacture or process cosmetics for U.S. distribution must register with the FDA. Foreign facilities must also designate a U.S. agent.
• Product Listing — Each cosmetic product must be listed with the FDA, including its ingredients, by the responsible person (brand owner or distributor).
• Adverse Event Reporting — Mandatory reporting of "serious adverse events" within 15 days. This did not exist for cosmetics before MoCRA.
• Safety Substantiation — Brands must have "adequate evidence" that their products are safe under labeled or customary conditions of use.
• Good Manufacturing Practices (GMP) — MoCRA mandates the FDA to establish GMP regulations for cosmetics, aligned with international standards (ISO 22716).
• Fragrance Allergen Disclosure — Specific fragrance allergens must now appear on labels (forthcoming FDA rule).

How MoCRA Specifically Affects K-Beauty and J-Beauty Brands

Korean and Japanese cosmetic brands face specific MoCRA challenges:

• Quasi-drug boundary — Many popular K-Beauty and J-Beauty products (whitening creams, UV filters, hair growth tonics) are classified as "quasi-drugs" in Korea or "quasi-drugs" (医薬部外品) in Japan. Under U.S. law, these may be regulated as OTC drugs, not cosmetics.
• Ingredient restrictions — Ingredients commonly used in Asian formulations may be restricted, banned, or require specific concentrations in the U.S. Check each ingredient's status using our cosmetic compliance checker.
• Labeling language — MoCRA requires English-language labels with specific information including the responsible person, product listing number, and full ingredient declaration using INCI names.
• U.S. Agent requirement — Foreign manufacturers must designate a U.S. agent for FDA communications — a new obligation for many Asian brands.

MoCRA-Affected Ingredients to Watch

MoCRA expands the FDA's authority to restrict or ban cosmetic ingredients. High-risk categories for Asian brands include:

• UV filters — Many UV filters approved in Korea and Japan (e.g., ensulizole variants) are not approved for U.S. OTC drug monograph use.
• Whitening agents — Arbutin, niacinamide at drug concentrations, and hydroquinone have specific regulatory boundaries. Hydroquinone is banned in OTC cosmetics.
• Preservatives — Some preservatives commonly used in Asian formulations have Prop 65 implications or concentration limits in the U.S.
• Color additives — All color additives in cosmetics must come from FDA-certified batches. See our checker for approved color additive listings.
• PFAS and formaldehyde releasers — Under MoCRA, the FDA has new authority to require reporting and potentially restrict these ingredient classes.

MoCRA Compliance Checklist for Exporters

1. Register your facility with the FDA (including designating a U.S. agent if foreign).
2. List each product with the FDA, including complete ingredient lists using INCI nomenclature.
3. Verify every ingredient — Check for restrictions, Prop 65 listings, color additive certification, and drug-cosmetic boundaries.
4. Establish a safety substantiation file for each product (toxicological assessments, patch tests, clinical studies).
5. Set up adverse event reporting — Designate a responsible person to receive and report serious adverse events within 15 days.
6. Audit your labels — Ensure English-language labels with responsible person info, product listing number, and full ingredient declaration.
7. Implement GMP — Align manufacturing practices with ISO 22716 and forthcoming FDA cosmetic GMP rules.

This guide is for informational purposes only and does not constitute legal or regulatory advice. MoCRA implementation rules are still being finalized by the FDA. Always review the latest FDA guidance and consult a qualified regulatory professional for your product. Not affiliated with the U.S. FDA. IngredientCompliance is an independent tool operated by Gerim-Sterling LLC.